eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | parathyroid carcinoma |
| Symptom | C0020437|hypercalcemia |
| Sentences | 4 |
| PubMedID- 21461394 | Since the approval of cinacalcet hcl for the therapy of secondary hyperparathyroidism (shpt) and hypercalcemia due to parathyroid carcinoma in 2004, calcimimetic therapy has become daily routine especially for clinical nephrologists worldwide. |
| PubMedID- 22363762 | The average monthly increase in patients for the fda-approved orphan indication (hypercalcemia in patients with parathyroid carcinoma) was 0.03 (95% ci: 0.01–0.05). |
| PubMedID- 20382129 | The second approved use of cinacalcet is for treating hypercalcemia in patients with inoperable parathyroid carcinoma. |
| PubMedID- 25667369 | Our objective is to present a case of successful management of resistant hypercalcemia due to parathyroid carcinoma with denosumab, to review similar cases from the literature, and to propose denosumab's use in the clinical management of pth-induced refractory hypercalcemia methods: presentation of a case report and review of the literature for cases of parathyroid carcinoma-mediated hypercalcemia successfully treated with denosumab. |
Page: 1